{
    "id": "34f352d5-bdca-df12-e063-6294a90a54bd",
    "indications": "atovaquone oral suspension quinone antimicrobial indicated : • prevention pneumocystis jirovecii pneumonia ( pcp ) adults adolescents aged 13 years older tolerate trimethoprim-sulfamethoxazole ( tmp-smx ) . ( 1.1 ) •treatment mild-to-moderate pcp adults adolescents aged 13 years older tolerate tmp-smx . ( 1.2 ) limitations ( 1.3 ) : • treatment severe pcp ( alveolar arterial oxygen diffusion gradient [ ( a-a ) 2 ] > 45 mm hg ) atovaquone oral suspension studied . • efficacy atovaquone oral suspension subjects failing therapy tmp-smx also studied .",
    "contraindications": "• prevention pcp : 1,500 mg ( 10 ml ) daily food ( 2.1 ) • treatment pcp : 750 mg ( 5 ml ) twice daily food 21 days ( 2.2 ) • supplied bottles : shake bottle gently . ( 2.3 )",
    "warningsAndPrecautions": "atovaquone oral suspension , usp yellow homogenous suspension containing 750 mg atovaquone usp per 5 ml . • bottle 210 ml child-resistant cap ( ndc 31722-629-21 ) . store 15° 25°c ( 59° 77°f ) . freeze . dispense tight container defined usp .",
    "adverseReactions": "atovaquone oral suspension contraindicated patients develop history hypersensitivity ( e.g . , angioedema , bronchospasm , throat tightness , urticaria ) atovaquone components atovaquone oral suspension .",
    "ingredients": [
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY"
        },
        {
            "name": "ATOVAQUONE",
            "code": "Y883P1Z2LT"
        }
    ],
    "organization": "ATLANTIC BIOLOGICALS CORP.",
    "name": "Atovaquone",
    "effectiveTime": "20250512",
    "indications_original": "Atovaquone oral suspension is a quinone antimicrobial drug indicated for: • Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1) •Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX . (1.2) Limitations of Use (1.3): •  Treatment of severe PCP (alveolar arterial oxygen diffusion gradient  [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral suspension has not been studied. •  The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied.",
    "contraindications_original": "• Prevention of PCP: 1,500 mg (10 mL) once daily with food (2.1) • Treatment of PCP: 750 mg (5 mL) twice daily with food for 21 days (2.2) • Supplied in Bottles: Shake bottle gently before use. (2.3)",
    "warningsAndPrecautions_original": "Atovaquone oral suspension, USP is a yellow homogenous suspension containing 750 mg atovaquone USP per 5 mL. \n    • Bottle of 210 mL with child-resistant cap (NDC 31722-629-21). Store at 15° to 25°C (59° to 77°F).\n \n  Do not freeze. Dispense in tight container as defined in USP.",
    "adverseReactions_original": "Atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral suspension."
}